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Abstract
Aim To analyse the cost-effectiveness of different interventions for Type 2 diabetes prevention within a common
framework.
Methods A micro-simulation model was developed to evaluate the cost-effectiveness of a range of diabetes prevention
interventions including: (1) soft drinks taxation; (2) retail policy in socially deprived areas; (3) workplace intervention;
(4) community-based intervention; and (5) screening and intensive lifestyle intervention in individuals with high diabetes
risk. Within the model, individuals follow metabolic trajectories (for BMI, cholesterol, systolic blood pressure and
glycaemia); individuals may develop diabetes, and some may exhibit complications of diabetes and related disorders,
including cardiovascular disease, and eventually die. Lifetime healthcare costs, employment costs and quality-adjusted
life-years are collected for each person.
Results All interventions generate more life-years and lifetime quality-adjusted life-years and reduce healthcare
spending compared with doing nothing. Screening and intensive lifestyle intervention generates greatest lifetime net
benefit (£37) but is costly to implement. In comparison, soft drinks taxation or retail policy generate lower net benefit
(£11 and £11) but are cost-saving in a shorter time period, preferentially benefit individuals from deprived backgrounds
and reduce employer costs.
Conclusion The model enables a wide range of diabetes prevention interventions to be evaluated according to cost-
effectiveness, employment and equity impacts over the short and long term, allowing decision-makers to prioritize policies
that maximize the expected benefits, as well as fulfilling other policy targets, such as addressing social inequalities.
Diabet. Med. 34, 1136–1144 (2017)
Introduction
Over 35% of adults in England are thought to be at high
risk of developing type 2 diabetes because of impaired
glucose regulation [1], defined by the American Diabetes
Association as HbA1c concentrations of 39–46 mmol/mol
(5.7–6.4%). There is now a wealth of evidence that diabetes
prevention through lifestyle change for people with
impaired glucose regulation is effective [2] and cost-effective
[3], and current National Institute for Health and Care
Excellence (NICE) guidelines recommend that individuals at
high risk of diabetes [fasting plasma glucose levels 5.5–
6.9 mmol/L or HbA1c 42–46 mmol/mol (6.0–6.4%)] are
offered an intensive programme of lifestyle change [4]. In
the UK, a National Diabetes Prevention Programme is being
implemented; however, interventions targeting the obeso-
genic environment may be more cost-effective, given that
the risk factors overlap with other non-communicable
diseases and many people benefit from improvements in
diet and lifestyle.
A review identified several diabetes models that have
investigated the cost-effectiveness of diabetes prevention
and policies, including intensive lifestyle intervention for
individuals at high risk of diabetes, weight loss interventions
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for obese/overweight individuals and lifestyle promotion
through fiscal or media campaigns [5]; however, because of
differences in model structure it is not possible to compare
interventions across studies and no study has directly com-
pared the cost-effectiveness of intensive lifestyle intervention
for individuals at high risk of diabetes within broader weight
loss policies in a single modelling framework or estimated
how outcomes are distributed across socio-economic groups.
The aims of the present study were to evaluate the
economic benefits of a range of intervention types within a
common modelling framework to help prioritize campaigns
according to cost-effectiveness and equity considerations, as
well as to report the short-term cost impact, distribution of
outcomes across socio-economic groups, and implications
for work productivity.
Methods
Model
The analysis was designed to evaluate lifetime costs and
health outcomes of diabetes prevention policies in England.
The model was developed using a novel conceptual mod-
elling framework [6], based on literature reviews and in
consultation with a stakeholders group of diabetes clinicians,
researchers and public health commissioners. The stake-
holder group of lay members, clinicians, researchers and
public health commissioners met three times to agree the
conceptual model, model structure, data inputs and policy
interventions. The model was an individual level simulation,
written using R software, which allows individual partici-
pants to be recruited into interventions conditional on their
characteristics. Baseline individual characteristics were
obtained from the Health Survey for England 2011, which
is a representative sample of the population in England [7].
Individuals with diabetes and those aged < 16 years were
excluded from analysis. Individuals were sampled at random
with replacement from this dataset to populate the model in
which 5 000 000 individuals were simulated. In the model,
each individual follows trajectories for HbA1c, BMI, systolic
blood pressure and cholesterol derived from the Whitehall II
cohort [8]. In yearly cycles, people visit their general
practitioner and may be diagnosed with diabetes, hyperten-
sion or dyslipidaemia and treated accordingly. The model
simulates a number of health outcomes that are related to
BMI and diabetes. Each year, individuals are at risk of
developing cardiovascular disease (QRISK2 [9]), heart failure
(Framingham study [10]), microvascular complications of
diabetes (UK Prospective Diabetes Study [11]), breast or
colon cancer [12,13], osteoarthritis [14], depression [15], or
they may die. A detailed description of the model methods,
assumptions, variables and validation tests can be found in
the Supporting Information, supplementary methods.
Healthcare costs and quality of life
Healthcare costs were assigned to the health states in the
model to estimate costs from aNational Health Service (NHS)
and Personal Social Services (PSS) perspective in 2014–2015
UK pounds. It was not feasible to accurately capture all
impacts of these interventions from a societal perspective
without making substantial assumptions and approximations
that would render the final estimate irrelevant. We favour
reporting the net benefit from an NHS/PSS perspective, with
supplementary information on workplace productivity, to
target the analysis at public health and healthcare profession-
als interested in diabetes prevention. EQ-5D health question-
naire scores were extracted from the Health Survey for
England dataset to describe an individual’s baseline health-
related quality of life, and utility decrements were applied in
each year of a person’s life according to age and health status.
Work productivity and employer costs
The model was designed to estimate work absence, condi-
tional on health status in employed individuals. The cost to the
employer was calculated based on the number of days absent
from work. Productivity losses were estimated using the
friction cost method, which assumes that there was sufficient
unemployment to replace workers on sick leave after a friction
period. The employer incurred a recruitment cost of a
replacement worker if an individual died whilst employed.
Interventions
A series of interventions were selected for inclusion in the
model (see Supporting Information, supplementary methods
for more details). Details of the target population, uptake,
effectiveness and costs of the interventions are reported in
Table 1.
What’s new?
• A novel model was developed to help policy-makers
decide which diabetes prevention interventions to pur-
sue, balancing cost-effectiveness against other objectives,
such as equity, employment and short-term return.
• Most interventions examined were cost-saving over a
lifetime compared with doing nothing.
• Individual-based intervention in high-risk individuals is
likely to be the most cost-effective option in the long
run, whilst population- and community-based interven-
tions are more equitable, reduce employer costs and are
cost-saving over shorter timescales.
• The model can easily be adapted to evaluate new
interventions as they are trialled, and help design local
and national diabetes and obesity prevention pro-
grammes.
ª 2017 The Authors.
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Sugar-sweetened soft drinks
The effect of a 20% soft drinks tax on mean BMI was
estimated previously [16]. The age-dependent effect was
applied to the general population. No costs were associated
with the soft drinks taxation scheme, nor was revenue
included in the NHS and PSS perspective.
Retail provision of fruit and vegetables
A supermarket opening was studied to observe the impact of
retail provision on local fruit and vegetable consumption
[17]. Fruit and vegetable consumption increased by 0.162
portions per day after the store opened. The change in fruit
and vegetable consumption was related directly to changes in
HbA1c and systolic blood pressure. Individuals in the highest
index of multiple deprivation (IMD) quintile (low socio-
economic status) received the intervention. The costs were
assumed to be incurred by the private sector.
Worksite healthy eating promotion
The Heartbeat Award scheme implemented healthy food
options in cafeterias in the workplace and observed the
impact on workers’ dietary patterns [18]. The study reported
the proportion of individuals who made a positive switch to
healthier food options compared with non-participating
workplaces. The benefits of the workplace intervention were
described by the increase in fruit consumption and the
switching of milk from a high- to a low-fat choice, and were
assumed to affect 20% of the working population.
Deprived community education programmes
Two community education programmes were identified to
describe the effectiveness of targeted education interventions
in deprived communities. Firstly, community nurses in a
deprived area of Scotland developed a group-based weight
management intervention specifically for obese men [19].
Secondly, a Mediterranean diet class was run for socially
deprived women [20]. Both studies reported mean change in
BMI and change in fruit and vegetable consumption. These
interventions were combined such that, within the same
scenario, women in the highest IMD quintile were offered a
cooking class, whilst men with a BMI > 30 kg/m2 and in the
highest IMD quintile were offered the diet programme.
Translational diabetes prevention programme
An individual’s risk of diabetes was assessed using the
Leicester Risk Score [21] whilst he or she attended for
vascular checks [22], and the individual was invited for
diabetes screening if the score was > 4.75. An NHS vascular
checks attendance rate of 43.7% was assumed in line with a
review of NHS health checks [23] and an intervention uptake
rate of 32% based on estimates from Public Health England
[24]. Individuals who attended screening with HbA1c
≥ 47.5 mmol/mol (6.5%) were diagnosed with diabetes.
Individuals with HbA1c ≥ 42.5 mmol/mol (6.0%), and not
diagnosed with diabetes were offered the lifestyle pro-
gramme. A meta-analysis of translational diabetes prevention
programmes was used to estimate the change in BMI, HbA1c,
systolic blood pressure and cholesterol at 12 months after a
lifestyle intervention [22]. It was assumed that individuals
received 6-monthly maintenance classes for 3 years after the
first year’s programme.
Maintenance of intervention effectiveness
Data were not available for the maintenance of metabolic
changes for each intervention. The effectiveness decreased
linearly after the first year, reaching zero effect after 5 years,
in line with observations from studies of dietary counselling
for weight loss [25].
Outcomes of the model
The results describe the benefits of the interventions com-
pared with a do-nothing strategy. Health benefits were
measured in quality-adjusted life years (QALYs). The ben-
efits of the interventions were also described in natural units
such as health events. Costs and QALYs were discounted at
1.5% per year. Incremental net benefit was estimated from
the NHS/PSS perspective to describe the overall monetary
benefit of the interventions in a single unit by assuming a
willingness to pay (k) of £20,000 per QALY.
Incremental net benefit ¼ kðincremental QALYÞ
ðincremental costÞ
Cost-effectiveness analysis included a lifetime perspective,
in line with NICE guidelines [26]. In addition, net benefit
over 5 and 10 years was obtained to describe short-term
cost-effectiveness. The results were disaggregated by depri-
vation quintiles to enable consideration of the distribution of
benefits across socio-economic groups. Differences in the
effectiveness of the interventions did not vary across depri-
vation quintiles; however, the characteristics and potential to
benefit from the interventions is variable. Days absent from
work and employer costs are reported separately from the
cost-effectiveness analysis to preserve the NHS/PSS perspec-
tive.
One-way sensitivity analysis was conducted to examine the
impact of the intervention assumptions and model variables
on the incremental net benefit outcomes. A probabilistic
sensitivity analysis was conducted to describe the uncertainty
in the model outcomes, for which appropriate statistical
distributions were assigned to all uncertain model parameters
(Supplementary methods).
Results
Table 2 shows the lifetime incremental differences between
the five interventions and doing nothing in health units and
cost-effectiveness outcomes. The retail policy, workplace
ª 2017 The Authors.
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intervention and community interventions reduce the num-
ber of diabetes diagnoses. The screening and intensive
lifestyle intervention for individuals at high risk of diabetes
increases the number of diabetes diagnoses over a lifetime by
2102 cases per 5 000 000 in the general population. This is
because the screening strategy increases life expectancy and
substantially improves identification of diabetes cases that
would otherwise remain undiagnosed but are still associated
with a high risk of diabetes-related complications and death.
All interventions decrease the incidence of cardiovascular
disease, congestive heart disease and cardiovascular death
over the lifetime perspective (Table 2). The screening and
intensive lifestyle intervention substantially reduces the
incidence of microvascular disease and increases the inci-
dence of depression [27]. In some cases, other interventions
slightly increase the incidence of foot ulcer, amputation and
cancer-specific death because of the increase in life
expectancy.
All interventions generate more life-years and lifetime
QALYs compared with a do-nothing scenario (Table 2). All
interventions, except community dietary advice, reduce
healthcare spending. The incremental net benefit is a statistic
that describes the overall value of each intervention per
person in the general population, and is calculated from the
costs saved and health benefits valued at £20,000 per QALY.
The screening and intensive lifestyle intervention in individ-
uals with a high risk of diabetes generates the greatest
incremental net benefit (£37), with a soft drinks taxation
coming second in our analysis (£11). The screening and
lifestyle intervention has a negative net benefit at 5 and
10 years because it takes longer to re-coup the costs of the
intervention. The retail intervention and soft drinks tax,
which incur no costs to the health provider, generate the
greatest 5-year, and 10-year incremental net benefit. An
incremental analysis in Table S1 comparing all intervention
strategies found that the screening and intensive lifestyle
intervention dominates all other options over a lifetime.
Figure 1 summarizes the distribution of lifetime QALYs
and costs across the five quintiles of deprivation. The retail
policy and community interventions generate benefits only in
the lowest quintile because these interventions are targeted at
the most deprived groups by design. The workplace inter-
vention and intensive lifestyle intervention in individuals at
high risk of diabetes have an even spread of benefits across
quintiles, whereas the soft drinks taxation offers increased
benefits to the most deprived. The interventions do not
assume differential effects between socio-economic groups,
therefore, the results are attributable to differences in
baseline characteristics and underlying risks of disease
progression inherent in the individuals targeted by the
interventions. For example, the low socio-economic group
tends to be younger and more likely to be affected by the soft
drinks tax.
The wider social impacts of these interventions were
considered by looking at the effects on employment
(Table 3). The retail, community and intensive lifestyle
interventions increase the number of days of work absence
over a lifetime compared with doing nothing. The overall
Table 2 Incremental health and cost outcomes of interventions compared with ‘do nothing’ per 5 000 000 simulated individuals in the general
population
Soft drinks tax Retail policy
Workplace
health promotion
Community
dietary advice
Intervention for
individuals at high risk
Events per 5 000 000 simulated individuals from the general population
Diabetes diagnosis 18 268 16 24 2102
Cardiovascular disease 30 37 23 19 663
Congestive heart failure 13 35 7 25 64
Cardiovascular death 8 13 13 13 326
Foot ulcer 3 2 3 1 551
Amputation 18 40 17 10 667
Blindness 2 42 6 5 1159
Renal failure 2 12 1 2 23
Osteoarthritis 280 68 7 92 87
Depression 1 0 1 9 505
Cancer death 17 6 2 7 7
Life years 324 2869 565 167 5571
QALYs* 1495 1828 531 372 3301
Mean difference per individual in the general population
QALYs* 0.0003 0.0004 0.0001 0.0001 0.0007
Healthcare costs (lifetime)* £4.80 £3.35 £0.56 £0.00 £23.85
Net benefit (5 years)* £1.96 £2.18 £0.10 £0.67 £5.09
Net benefit (10 years)* £4.16 £5.55 £0.68 £0.05 £1.87
Net benefit (lifetime)* £10.78 £10.66 £2.68 £1.48 £37.05
QALY, quality-adjusted life-year.
*Discounted at 1.5%.
QALYs valued at £20,000 per QALY for net benefit calculations.
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impact on the employer costs per individual in employment
(56.3% of population) suggests that the soft drinks tax, retail
policy, workplace intervention and community interventions
generate cost savings for the employer (ranging from £0.01 to
£0.12 per individual in employment); however, the screening
and intensive lifestyle intervention for individuals at high risk
of diabetes is more costly to employers than doing nothing
(£0.43 per individual in employment). This counterintuitive
result arises because of the increase in the number of
individuals with diabetes and, as a consequence, an increase
in depression [27], both associated with a high level of work
absence; however, to explore uncertainty about this assump-
tion, a sensitivity analysis was performed in which depres-
sion and work absence were associated with the onset of
diabetes, rather than diagnosis; in this case, the intensive
lifestyle intervention saves money for employers (£0.05 per
individual in employment).
Table S4 describes the results of the other one-way
sensitivity analyses. These suggest that the results are very
sensitive to the rate of weight regain assumed in the model.
The education interventions for deprived communities and
individuals at high risk of diabetes are also very sensitive to
the assumed uptake rates of these interventions. This
highlights the importance of recruitment and retention of
individuals in education programmes. A sensitivity analysis
for HbA1c testing without lifestyle intervention for individ-
uals at high risk results in a net benefit of approximately £25
per person, suggesting that a policy identifying individuals
with undiagnosed diabetes alone is also highly cost-effective.
Outcomes for all interventions were sensitive to the discount
rate used, but most results were fairly insensitive to non-
intervention model variables. The intervention for individu-
als at high risk of diabetes, however, was sensitive to diabetes
related costs because of the number of individuals diagnosed
with diabetes as a result of this screening and intervention
process.
The probabilistic sensitivity analyses are summarized in
Fig. 2 and in the Supporting Information, supplementary
results. Figure 2a shows that the screening and intensive
lifestyle intervention has ~78% probability of being the most
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FIGURE 1 Lifetime incremental costs and QALYs compared to doing nothing, by deprivation quintile from simulation of five million adults in the
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Table 3 Lifetime incremental day of work absence per 5 000 000 simulated individuals, deaths whilst in employment per 5 000 000 simulated
individuals and overall employer cost per individual in employment at baseline compared with a do-nothing strategy
Soft drinks
tax
Retail
policy
Workplace
health
promotion
Community
dietary
advice
Intervention
for individuals
at high risk
(a) Baseline analysis assuming work absence after diabetes diagnosis
Days absent from work 5118 3181 2102 854 31044
Deaths whilst in employment 5 35 20 0 46
Employer cost per individual in employment at baseline* £0.12 £0.05 £0.03 £0.02 £0.43
(b) Sensitivity analysis assuming work absence after diabetes onset (diagnosed plus undiagnosed)
Days absent from work 6106 2253 1473 321 919
Deaths whilst in employment 9 9 7 1 8
Employer cost per individual in employment at baseline* £0.11 £0.02 £0.01 £0.01 £0.05
*Discounted at 1.5%.
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cost-effective strategy above a threshold of £20,000 per
QALY gained and Figure 2a shows that this intervention
maximizes net benefit at all willingness-to-pay thresholds.
Discussion
The present analysis showed that the intensive lifestyle
intervention in individuals at a high risk of diabetes would
generate the largest benefits; however, this intervention
would not reduce health inequalities in society, and might
marginally increase the costs to employers. Furthermore, cost
savings take many years to accrue, meaning that, in the short
term, the intensive intervention is less cost-effective to the
NHS than the other interventions. By contrast, soft drinks
taxation or the retail policy would generate less overall net
benefit over a lifetime, but a greater proportion of those who
benefit would be in the most deprived groups. These
interventions would be marginally cost-saving for employers
and cost-savings for the NHS would accrue more quickly.
The analysis supports the introduction of two policies
currently being implemented in the UK. The NHS Diabetes
Prevention Programme will start in 2016 with a first wave of
27 areas making up to 20 000 places available. This will roll
out to the whole country by 2020 with an expected 100 000
referrals available each year after. The present analysis shows
that the programme will most likely be cost-saving to the
NHS over the lifetime of the patients, and is substantially
more cost-saving than alternative diabetes prevention strate-
gies we have evaluated. In April 2018 a tax will be imposed
on sugar-sweetened drinks in the UK. We have shown that a
20% tax is likely to result in cost-savings to the NHS and
QALY gains and that the benefits are greatest amongst the
most deprived socio-economic groups.
The analysis found that the community intervention in a
deprived area would be the least cost-effective intervention.
Sensitivity analysis indicates that the poor performance of
this intervention compared with the lifestyle intervention in
individuals at high risk of diabetes is attributable to the low
uptake of the intervention in this population, and does not
capture the benefits of identifying undiagnosed diabetes. It is
possible that changes to the choice environment, as demon-
strated by the retail intervention or soft drinks tax, may be
more cost-effective in the most deprived communities.
In recent years, several other studies have considered the
cost-effectiveness of multiple interventions targeting different
groups within the general population. There are some
common findings, for example, that less intensive interven-
tions targeting a broad population are cost-effective [28,29]
and are more cost-effective when targeting younger adults
[29], and that individual counselling and fiscal measures are
more cost-effective than workplace interventions [28]. The
present analysis has two major strengths compared with
previous diabetes prevention studies [30]. Firstly, the flexi-
bility of the model allows input of multiple population-level
scenarios, including a range of different interventions and
different population subgroups targeted. Secondly, the
breadth of outcomes generated for each intervention, includ-
ing net benefit to the NHS in the short and long term and
impact on socio-economic groups and employers. This means
that the model can be adapted to suit a wide range of
potential decision problems that may arise.
The present analysis has shown that most interventions are
cost-saving over the lifetime horizon. In contrast, previous
modelling of the health economic consequences of diabetes
prevention in the UK suggested that the cost of the
intervention would exceed the expected healthcare savings
[31,32]. This difference can be attributed to several factors:
(1) the cost of diabetes management in early stages of disease
is lower in this model following recommendations from
clinical experts; (2) the inclusion of renal failure and
osteoarthritis generates substantial cost savings for interven-
tions over the long term; and (3) the cost of treating
cardiovascular disease has increased.
There are several limitations of the model, many of which
arise as a result of assumptions that have had to be made
when implementing interventions because of lack of data, for
example, concerning rate of weight regain, or because of
indirect estimations of intervention efficacy. Sensitivity anal-
ysis has been performed to explore these issues and indicates
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FIGURE 2 (a) Cost-effectiveness acceptability curve showing the
probability of being cost-effective of all five interventions and a do-
nothing scenario. (b) Cost-effectiveness acceptability frontier showing
the option maximizing net benefit.
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that whereas model results are relatively stable to alteration
of general model variables, those concerning the intervention
can have dramatic effects on intervention cost-effectiveness.
To reduce uncertainty in such analyses, more evidence is
needed on the long-term duration of benefits, the uptake of
interventions in different population sub-groups and the
direct effects of interventions on metabolic trajectories.
Cost-effectiveness is not the only issue of importance for
public health policy-makers; other targets such as addressing
social inequalities are also important [33]. We present the
relative distribution of incremental costs and QALYs for
each intervention (Fig. 1); however, we have not varied the
effectiveness of the interventions by sub-group for the soft
drinks tax, workplace intervention or intensive lifestyle
programme. It is possible that the interventions will have
differential effectiveness according to baseline BMI or socio-
economic group. The evidence suggested almost no differ-
ences in effectiveness of the soft drinks tax by income group
[16], and no evidence was available to describe the effec-
tiveness of the workplace intervention or intensive lifestyle
programme by socio-economic group or baseline BMI.
Further research is needed to examine in more detail the
differential impact of these policies on sub-groups. Our
validation work indicates that the model may overestimate
HbA1c and systolic blood pressure in people with newly
diagnosed diabetes, which may bias the cost-effectiveness
outcomes. There is a paucity of up-to-date data, however, on
metabolic trajectories for patients with diabetes to investi-
gate whether this underestimate persists in the long term.
There are several avenues for further research to extend the
analysis to other policy areas and reduce uncertainty in the
model. The model is sufficiently flexible to investigate the
effect of layering multiple interventions across overlapping
target populations. Another area for future model develop-
ment would be to add in the effects of changes on physical
activity, a common target for diabetes prevention interven-
tions. Unpicking the differential effects of physical activity and
dietary change/weight loss would be highly informative to
developers of diabetes prevention programmes. Further exten-
sions of the model to describe smoking and alcohol consump-
tion would allow analyses of other public health policies.
Finally,wedonot currently account for non-related healthcare
costs that may have an impact on the results, particularly
where interventions improve survival [34]. Current NICE
guidelines [26] donot require inclusionof unrelated healthcare
costs, but we believe that the model would benefit from
inclusion of other health outcomes, such as dementia.
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